Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 10.60% is 20% above its 5-year average of 8.86%, near the high end of its 5-year range (4.75%–11.12%).
7.94% above its 12-month average of 9.82%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 3.06%.
RETURN ON ASSETS (ROA)
10.60%
RETURN ON ASSETS (ROA) AVG TTM
9.82%
RETURN ON ASSETS (ROA) AVG 3Y
10.45%
RETURN ON ASSETS (ROA) AVG 5Y
8.86%
RETURN ON ASSETS (ROA) AVG 10Y
8.22%
RETURN ON ASSETS (ROA) AVG 15Y
9.04%
RETURN ON ASSETS (ROA) AVG 20Y
8.68%
CURRENT VS TTM AVG
+7.94%
CURRENT VS 3Y AVG
+1.41%
CURRENT VS 5Y AVG
+19.68%
CURRENT VS 10Y AVG
+29.03%
CURRENT VS 15Y AVG
+17.23%
CURRENT VS 20Y AVG
+22.17%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+132.85%
vs the sector median at left
UFP Technologies, Inc.
Market Cap
$2.34B
Return on Assets (ROA)
10.60%
TTM Avg
9.82%
3Y Avg
10.45%
5Y Avg
8.86%
Market Cap
$2.35B
Return on Assets (ROA)
-63.74%
TTM Avg
-33.67%
3Y Avg
-37.78%
5Y Avg
-31.10%
Market Cap
$2.36B
Return on Assets (ROA)
24.69%
TTM Avg
32.00%
3Y Avg
9.13%
5Y Avg
-4.32%
Market Cap
$2.37B
Return on Assets (ROA)
-33.45%
TTM Avg
-24.16%
3Y Avg
-23.12%
5Y Avg
-103.71%
Market Cap
$2.30B
Return on Assets (ROA)
26.56%
TTM Avg
-38.82%
3Y Avg
-43.93%
5Y Avg
-45.44%
Market Cap
$2.38B
Return on Assets (ROA)
-2.55%
TTM Avg
-11.61%
3Y Avg
-25.65%
5Y Avg
-35.91%
Market Cap
$2.28B
Return on Assets (ROA)
13.20%
TTM Avg
13.52%
3Y Avg
17.46%
5Y Avg
11.53%
Market Cap
$2.43B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$2.24B
Return on Assets (ROA)
-21.30%
TTM Avg
-10.65%
3Y Avg
-10.65%
5Y Avg
-10.65%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UFP Technologies, Inc. (UFPT) | $2.34B | 10.60% | 9.82% | 10.45% | 8.86% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -63.74% | -33.67% | -37.78% | -31.10% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 24.69% | 32.00% | 9.13% | -4.32% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | -33.45% | -24.16% | -23.12% | -103.71% |
| Liquidia Corporation (LQDA)vs › | $2.30B | 26.56% | -38.82% | -43.93% | -45.44% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -2.55% | -11.61% | -25.65% | -35.91% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 13.20% | 13.52% | 17.46% | 11.53% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -42.79% | -37.88% | -40.02% | -36.63% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -21.30% | -10.65% | -10.65% | -10.65% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.49B | -7.69% | 1.38% | 1.60% | 3.00% |
ROA
10.6%
ROE
15.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 10.26% |
| 2024-12-31 | 9.38% |
| 2023-12-31 | 11.12% |
| 2022-12-31 | 11.05% |
| 2021-12-31 | 4.75% |
| 2020-12-31 | 6.58% |
| 2019-12-31 | 10.46% |
| 2018-12-31 | 7.55% |
| 2017-12-31 | 6.66% |
| 2016-12-31 | 6.23% |
| 2015-12-31 | 6.33% |
| 2014-12-31 | 6.65% |
| 2013-12-31 | 10.74% |
| 2012-12-31 | 11.05% |
| 2011-12-31 | 12.98% |
| 2010-12-31 | 12.88% |
| 2009-12-31 | 9.97% |
| 2008-12-31 | 10.50% |
| 2007-12-31 | 9.13% |
| 2006-12-31 | 6.44% |
| 2005-12-31 | 1.50% |
| 2004-12-31 | 2.20% |
| 2003-12-31 | -4.12% |
| 2002-12-31 | -0.66% |
| 2001-12-31 | -7.99% |
| 2000-12-31 | 2.68% |
| 1999-12-31 | 5.33% |
| 1998-12-31 | 5.35% |
| 1997-12-31 | 5.16% |
| 1996-12-31 | 5.68% |
